Claire Dunn

  • Deputy group leader; PhD
  • +47 2278 14 23

Publications 2024

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Jin Y, Dunn C, Persiconi I, Sike A, Skorstad G, Beck C, Kyte JA (2024)
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers
Int J Mol Sci, 25 (1)
DOI 10.3390/ijms25010586, PubMed 38203757

Publications 2022

Dorraji E, Borgen E, Segura-Peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA (2022)
Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
Cancers (Basel), 14 (19)
DOI 10.3390/cancers14194859, PubMed 36230782

Jin Y, Lorvik KB, Jin Y, Beck C, Sike A, Persiconi I, Kvaløy E, Saatcioglu F, Dunn C, Kyte JA (2022)
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer
Mol Ther Oncolytics, 26, 189-206
DOI 10.1016/j.omto.2022.06.007, PubMed 35860008

Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103

Publications 2020

Etherson K, Dunn C, Matthews W, Pamelund H, Barragat C, Sanderson N, Izumi T, Mathews CDC, Halbert G, Wilson C, McAllister M, Mann J, Østergaard J, Butler J, Khadra I (2020)
An interlaboratory investigation of intrinsic dissolution rate determination using surface dissolution
Eur J Pharm Biopharm, 150, 24-32
DOI 10.1016/j.ejpb.2020.02.005, PubMed 32061919

McPherson S, Perrier J, Dunn C, Khadra I, Davidson S, Ainousah B, Wilson CG, Halbert G (2020)
Small scale design of experiment investigation of equilibrium solubility in simulated fasted and fed intestinal fluid
Eur J Pharm Biopharm, 150, 14-23
DOI 10.1016/j.ejpb.2020.01.016, PubMed 32035969

Publications 2019

Dunn C, Perrier J, Khadra I, Wilson CG, Halbert GW (2019)
Topography of Simulated Intestinal Equilibrium Solubility
Mol Pharm, 16 (5), 1890-1905
DOI 10.1021/acs.molpharmaceut.8b01238, PubMed 30848917

Khadra I, Obeid MA, Dunn C, Watts S, Halbert G, Ford S, Mullen A (2019)
Characterisation and optimisation of diclofenac sodium orodispersible thin film formulation
Int J Pharm, 561, 43-46
DOI 10.1016/j.ijpharm.2019.01.064, PubMed 30772459

Publications 2017

Ainousah BE, Perrier J, Dunn C, Khadra I, Wilson CG, Halbert G (2017)
Dual Level Statistical Investigation of Equilibrium Solubility in Simulated Fasted and Fed Intestinal Fluid
Mol Pharm, 14 (12), 4170-4180
DOI 10.1021/acs.molpharmaceut.7b00869, PubMed 29072917

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S et al. (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Oncoimmunology, 6 (3), e1277306
DOI 10.1080/2162402X.2016.1277306, PubMed 28405498

Perrier J, Zhou Z, Dunn C, Khadra I, Wilson CG, Halbert G (2017)
Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs
Eur J Pharm Sci, 111, 247-256
DOI 10.1016/j.ejps.2017.10.007, PubMed 28987539

Zhou Z, Dunn C, Khadra I, Wilson CG, Halbert GW (2017)
Influence of Physiological Gastrointestinal Surfactant Ratio on the Equilibrium Solubility of BCS Class II Drugs Investigated Using a Four Component Mixture Design
Mol Pharm, 14 (12), 4132-4144
DOI 10.1021/acs.molpharmaceut.7b00354, PubMed 28749696

Publications 2016

Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D, Dunn C, Fusai G, Male V, Davidson BR, Kennedy P, Maini MK (2016)
CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver
Sci Rep, 6, 26157
DOI 10.1038/srep26157, PubMed 27210614

Zhou Z, Dunn C, Khadra I, Wilson CG, Halbert GW (2016)
Statistical investigation of simulated fed intestinal media composition on the equilibrium solubility of oral drugs
Eur J Pharm Sci, 99, 95-104
DOI 10.1016/j.ejps.2016.12.008, PubMed 27940083

Publications 2014

Khadra I, Zhou Z, Dunn C, Wilson CG, Halbert G (2014)
Statistical investigation of simulated intestinal fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs
Eur J Pharm Sci, 67, 65-75
DOI 10.1016/j.ejps.2014.10.019, PubMed 25444845

Publications 2010

Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK (2010)
Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection
PLoS Pathog, 6 (12), e1001227
DOI 10.1371/journal.ppat.1001227, PubMed 21187913

Publications 2009

Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2009)
Temporal analysis of early immune responses in patients with acute hepatitis B virus infection
Gastroenterology, 137 (4), 1289-300
DOI 10.1053/j.gastro.2009.06.054, PubMed 19591831

Publications 2008

Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, Alexander G, Finney H, Lawson A, Plunkett FJ, Bertoletti A, Akbar AN, Maini MK (2008)
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
J Exp Med, 205 (9), 2111-24
DOI 10.1084/jem.20072076, PubMed 18695005

Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, Peppa D, Gilson RJ, Gehring A, Bertoletti A, Maini MK (2008)
Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection
J Clin Invest, 118 (5), 1835-45
DOI 10.1172/JCI33402, PubMed 18398508

Publications 2007

Dunn C (2007)
Assaying chemokines and chemotaxis
Expert Rev Clin Immunol, 3 (6), 849-50
DOI 10.1586/1744666X.3.6.849, PubMed 20477133

Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK (2007)
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage
J Exp Med, 204 (3), 667-80
DOI 10.1084/jem.20061287, PubMed 17353365

Publications 2005

Dunn C (2005)
Patient positioning
Nurs Stand, 20 (11), 67
DOI 10.7748/ns.20.11.67.s56, PubMed 16320966

Hegde NR, Dunn C, Lewinsohn DM, Jarvis MA, Nelson JA, Johnson DC (2005)
Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL
J Exp Med, 202 (8), 1109-19
DOI 10.1084/jem.20050162, PubMed 16216889

Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, Reignat S, Webster G, Bertoletti A, Maini MK (2005)
Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection
J Infect Dis, 191 (7), 1169-79
DOI 10.1086/428502, PubMed 15747254

Publications 2003

Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D (2003)
Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity
J Exp Med, 197 (11), 1427-39
DOI 10.1084/jem.20022059, PubMed 12782710

Publications 2002

Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, Johnson DC (2002)
Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation
J Virol, 76 (21), 10929-41
DOI 10.1128/jvi.76.21.10929-10941.2002, PubMed 12368336

Sriram V, Cho S, Li P, O'Donnell PW, Dunn C, Hayakawa K, Blum JS, Brutkiewicz RR (2002)
Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells
Proc Natl Acad Sci U S A, 99 (12), 8197-202
DOI 10.1073/pnas.122636199, PubMed 12060764

Page visits: 3176